Emily K. Jeng

4.3k total citations · 1 hit paper
39 papers, 2.3k citations indexed

About

Emily K. Jeng is a scholar working on Immunology, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Emily K. Jeng has authored 39 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Immunology, 17 papers in Oncology and 6 papers in Pathology and Forensic Medicine. Recurrent topics in Emily K. Jeng's work include Immune Cell Function and Interaction (29 papers), CAR-T cell therapy research (16 papers) and T-cell and B-cell Immunology (11 papers). Emily K. Jeng is often cited by papers focused on Immune Cell Function and Interaction (29 papers), CAR-T cell therapy research (16 papers) and T-cell and B-cell Immunology (11 papers). Emily K. Jeng collaborates with scholars based in United States, China and Switzerland. Emily K. Jeng's co-authors include Hing C. Wong, Feng Jiao, Peter R. Rhode, Sarah Alter, Mariane B. Melo, Ana P. Castaño, Darrell J. Irvine, Yiran Zheng, Li Tang and Na Li and has published in prestigious journals such as Journal of Biological Chemistry, Nature Communications and Blood.

In The Last Decade

Emily K. Jeng

38 papers receiving 2.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Enhancing T cell therapy through TCR-signaling-responsive nanoparticle drug delivery

2018 542 citations Li Tang, Yiran Zheng et al. Nature Biotechnology profile →

Peers

Countries citing papers authored by Emily K. Jeng

Since Specialization

Citations

This map shows the geographic impact of Emily K. Jeng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emily K. Jeng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emily K. Jeng more than expected).

Fields of papers citing papers by Emily K. Jeng

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Emily K. Jeng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emily K. Jeng. The network helps show where Emily K. Jeng may publish in the future.

Co-authorship network of co-authors of Emily K. Jeng

This figure shows the co-authorship network connecting the top 25 collaborators of Emily K. Jeng. A scholar is included among the top collaborators of Emily K. Jeng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Emily K. Jeng. Emily K. Jeng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Enhancing Hydrogen Diffusion in Catalytic Removal of Nitrate Using a Flow Reactor 2023 ·Topics in Catalysis ·Hongjie Tang, Emily K. Jeng, Yijin Kang, Yushan Yan, Bingjun Xu, Feng Jiao	1
2	Scalable Gas Diffusion Electrode Fabrication for Electrochemical CO₂ Reduction Using Physical Vapor Deposition Methods 2022 ·ACS Applied Materials & Interfaces ·Emily K. Jeng, Zhen Qi, (unknown), (unknown), Ziyang Huo, John S. Miller, L. B. Bayu Aji, Byung Hee Ko, Haeun Shin, Sichao Ma, Kendra P. Kuhl, Feng Jiao, Juergen Biener	36
3	The impact of nitrogen oxides on electrochemical carbon dioxide reduction 2020 ·Nature Communications ·Byung Hee Ko, Bjorn Hasa, Haeun Shin, Emily K. Jeng, Sean Overa, (unknown), Feng Jiao	128
4	Enhanced Lymphodepletion Is Insufficient to Replace Exogenous IL2 or IL15 Therapy in Augmenting the Efficacy of Adoptively Transferred Effector CD8+ T Cells 2018 ·Cancer Research ·Christopher Johnson, (unknown), Brian Riesenberg, Samantha Suriano, Shikhar Mehrotra, Elizabeth Garrett‐Mayer, Mohamed L. Salem, Emily K. Jeng, Hing C. Wong, Chrystal M. Paulos, John Wrangle, David J. Cole, Mark P. Rubinstein	7
5	Enhancing T cell therapy through TCR-signaling-responsive nanoparticle drug delivery breakdown → 2018 ·Nature Biotechnology ·Li Tang, Yiran Zheng, Mariane B. Melo, Llian Mabardi, Ana P. Castaño, Yuqing Xie, Na Li, Sagar B. Kudchodkar, Hing C. Wong, Emily K. Jeng, Marcela V. Maus, Darrell J. Irvine	542
6	Evaluation of the biological activities of the IL-15 superagonist complex, ALT-803, following intravenous versus subcutaneous administration in murine models 2018 ·Cytokine ·Bai Liu, Monica Jones, Lin Kong, (unknown), Emily K. Jeng, Sixiang Shi, Christopher G. England, Sarah Alter, Jeffrey S. Miller, Weibo Cai, Peter R. Rhode, Hing C. Wong	30
7	Interleukin-15 Complex Treatment Protects Mice from Cerebral Malaria by Inducing Interleukin-10-Producing Natural Killer Cells 2018 ·Immunity ·Kristina S. Burrack, Matthew A. Huggins, Emily Taras, (unknown), Christine Henzler, Rendong Yang, Sarah Alter, Emily K. Jeng, Hing C. Wong, Martin Felices, Frank Cichocki, Jeffrey S. Miller, Geoffrey T. Hart, Aaron J. Johnson, Stephen C. Jameson, Sara E. Hamilton	58
8	Abstract CT146: First-in-human phase I combination of the IL-15 receptor super agonist complex ALT-803 with a therapeutic (anti-CD20) monoclonal antibody (mAb) for patients with relapsed or refractory indolent non-Hodgkin lymphoma (iNHL) 2018 ·Cancer Research ·Todd A. Fehniger, Brian Hess, Veronika Bachanová, Michelle Becker‐Hapak, Ethan McClain, Melissa M. Berrien-Elliott, Julia A. Wagner, Nancy L. Bartlett, Brad S. Kahl, Neha Mehta–Shah, Amanda F. Cashen, Feng Gao, (unknown), Amy D. Rock, Emily K. Jeng, (unknown), Jack O. Egan, Peter R. Rhode, Hing C. Wong	6
9	The IL15 Superagonist Complex ALT-803 Potently Enhances the Proliferative Capacity and Activity of in Vitro Expanded Natural Killer Cells 2017 ·Blood ·Tarun K. Garg, Katie Stone, Amy D Greenway, Carolina Schinke, Sharmilan Thanendrarajan, Maurizio Zangari, Joshua Epstein, Brian A. Walker, Hing C. Wong, Emily K. Jeng, Niraj Shrestha, Faith E. Davies, Gareth J. Morgan, Frits van Rhee	1
10	Therapeutic Effects of a Novel Fusion of ALT-803, an IL-15 Superagonist, with 4 Single-Chains of Anti-CD20 Antibody (2B8T2M) in Combination with Expanded Natural Killer Cells Against Rituximab Sensitive and Resistant Burkitt Lymphoma (BL) 2017 ·Blood ·Yaya Chu, Nang Kham Su, Sarah Alter, Emily K. Jeng, Peter R. Rhode, Matthew J. Barth, Dean A. Lee, Hing C. Wong, Mitchell S. Cairo	1
11	Glycolytic requirement for NK cell cytotoxicity and cytomegalovirus control 2017 ·JCI Insight ·Annelise Y. Mah-Som, Armin Rashidi, Molly P. Keppel, Nermina Saucier, (unknown), Joshua B. Alinger, Sandeep K. Tripathy, Sandeep K. Agarwal, Emily K. Jeng, Hing C. Wong, Jeffrey S. Miller, Todd A. Fehniger, Emily M. Mace, Anthony R. French, Megan A. Cooper	101
12	Novel antitumor complexes of bispecific antibodies using ALT-803 as a scaffold demonstrate Tetra-specific binding activities 2017 ·The Journal of Immunology ·Bai Liu, Lin Kong, (unknown), Kaiping Han, Lijing You, Michael Dee, Peter R. Rhode, Emily K. Jeng, Sarah Alter, Hing C. Wong	1
13	A Novel Fusion of ALT-803 (Interleukin (IL)-15 Superagonist) with an Antibody Demonstrates Antigen-specific Antitumor Responses 2016 ·Journal of Biological Chemistry ·Bai Liu, Lin Kong, Kaiping Han, Hao Hong, Warren D. Marcus, Xiaoyue Chen, Emily K. Jeng, Sarah Alter, Xiaoyun Zhu, Mark P. Rubinstein, Sixiang Shi, Peter R. Rhode, Weibo Cai, Hing C. Wong	60
14	Abstract 3245: IL-15 superagonist/IL-15RαSushi-Fc fusion complex (IL-15SA/IL-15RαSu-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8+ T cells, and mediates potent anti-tumor activity of murine breast and colon carcinomas 2016 ·Cancer Research ·Peter Kim, Anna Kwilas, Wenxin Xu, Sarah Alter, Emily K. Jeng, Hing C. Wong, Jeffrey Schlom, James W. Hodge	1
15	In Vivo Activation of Human NK Cells by Treatment with an Interleukin-15 Superagonist Potently Inhibits Acute In Vivo HIV-1 Infection in Humanized Mice 2015 ·Journal of Virology ·(unknown), Candice D. Church, Jian Zheng, (unknown), Christina Ochsenbauer, John C. Kappes, Bai Liu, Emily K. Jeng, Hing C. Wong, Harris Goldstein	74
16	Comparison of the Superagonist Complex, ALT-803, to IL15 as Cancer Immunotherapeutics in Animal Models 2015 ·Cancer Immunology Research ·Peter R. Rhode, Jack O. Egan, Wenxin Xu, Hao Hong, Gabriela M. Webb, Xiaoyue Chen, Bai Liu, Xiaoyun Zhu, Jinghai Wen, Lijing You, Lin Kong, Ana C. Edwards, Kaiping Han, Sixiang Shi, Sarah Alter, Jonah B. Sacha, Emily K. Jeng, Weibo Cai, Hing C. Wong	170
17	Novel antitumor mechanism-of-action of an IL-2 fusion protein mediated by tumor associated macrophage repolarization and innate-like CD8+ memory T cells 2014 ·Journal for ImmunoTherapy of Cancer ·Wenxin Xu, Jack O. Egan, Bai Liu, Xiaoyue Chen, Lijing You, Kaiping Han, Warren D. Marcus, Lin Kong, Monica Jones, Emily K. Jeng, Peter R. Rhode, Hing C. Wong	1
18	Efficacy and Mechanism-of-Action of a Novel Superagonist Interleukin-15: Interleukin-15 Receptor αSu/Fc Fusion Complex in Syngeneic Murine Models of Multiple Myeloma 2013 ·Cancer Research ·Wenxin Xu, Monica Jones, Bai Liu, Xiaoyun Zhu, (unknown), Ana C. Edwards, Lin Kong, Emily K. Jeng, Kaiping Han, Warren D. Marcus, Mark P. Rubinstein, Peter R. Rhode, Hing C. Wong	157
19	The IL-15-based superagonist ALT-803 promotes the antigen-independent conversion of memory CD8⁺T cells into innate-like effector cells with antitumor activity 2013 ·OncoImmunology ·Hing C. Wong, Emily K. Jeng, Peter R. Rhode	62
20	IL-15:IL-15 receptor alpha superagonist complex: High-level co-expression in recombinant mammalian cells, purification and characterization 2011 ·Cytokine ·Kaiping Han, Xiaoyun Zhu, Bai Liu, Emily K. Jeng, Lin Kong, Jason L. Yovandich, Vinay Vyas, Warren D. Marcus, Pierre‐André Chavaillaz, (unknown), Peter R. Rhode, Hing C. Wong	169

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact